期刊文献+

口服磺脲类、二甲双胍联合胰岛素治疗控制不良的2型糖尿病患者加用罗格列酮的疗效观察 被引量:2

下载PDF
导出
摘要 目的:探讨口服磺脲类、二甲双胍联合胰岛素治疗控制不良的2型糖尿病应用罗格列酮的疗效。方法:将52例磺脲类、二甲双胍联合胰岛素治疗控制不良的2型糖尿病患者随机分为罗格列酮组和对照组。治疗12周后,观察两组的血糖控制、胰岛素用量、血脂、体重的变化。结果:治疗12周后,与对照组相比,罗格列酮组血糖控制良好,明显优于对照组(P<0.01),且胰岛素剂量减少21.7%,而对照组胰岛素剂量却增加了19.1%。罗格列酮组甘油三酯较前有明显下降(P<0.01),胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、体重与治疗前无明显变化(P>0.05)。结论:对于口服磺脲类、二甲双胍药联合胰岛素控制不良的2型糖尿病患者,加用罗格列酮能使血糖得到较好的控制,是一种有效安全的选择。
出处 《实用医学杂志》 CAS 2006年第15期1808-1810,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献8

  • 1United Kingdom Prospective Diabetes Study 24:a 6-year,randomized,controlled trail comparing sulfonylurea,insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy[J].Ann Intern Med,1998,128(3):165-175.
  • 2王毅飞,伊娜,张松,林延德.磺脲类合并二甲双胍失效的2型糖尿病患者应用胰岛素治疗和联合治疗方案的临床观察[J].实用医学杂志,2003,19(7):736-737. 被引量:2
  • 3王毅飞,伊娜,张松,徐谷根,林延德.胰岛素加用罗列酮治疗血糖控制不良的2型糖尿病患者疗效观察[J].中国实用内科杂志,2004,24(7):434-435. 被引量:5
  • 4SPIEGELMAN B M.PPAR-gamma:adipogenic regulator and thiazolidinedione receptor[J].Diabetes,1998,47(4):507-514.
  • 5YONG P W,CAWTHORNE M A,COYLE P J,et al.Repeat treatment of obese mice with BRL49653,a newlypotent insulin action in white adipocytes.Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling[J].Diabetes,1995,44(11):1087-1092.
  • 6JONES N P,MATHER R,OWEN S,et al.Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin[J].Diabetologia,2000,43 (Suppl 1):A192.
  • 7RASKIN P,RENDELL M,RIDDLE M C,et al.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes[J].Diabetes Care,2001,24(7):1226-1232.
  • 8BUCH H N,BASKAR V,BARTON D M,et al.Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes[J].Diabet Med,2002,19(7):572 -574.

二级参考文献11

  • 1UKPDS Group. A 6-year randomized prospective controlled trail comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnesed type 2 diabetes that could not be controlled with diet therapy.Ann Intern Med, 1998,128(2) : 165 ~ 175.
  • 2Ravnik-Oblak M, Mrevlje F. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. Diabetes Res Clin Pract,1995,30(1):27 ~ 35.
  • 3Rachman J, Levy JC, Barrow BA, et al. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. Diabetes, 1997,46(10) : 1557 ~ 1562.
  • 4Trischitta V, Italia S, Raimondo M, et al. Efficacy of combined treatments in NIDDm patients with secondary failure to sulphonylureas.Is it pridectable? J Endocrinol Invest, 1998,21(11):744 ~ 777.
  • 5Chow CC, Tsang LW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care, 1995,18 ( 3 ) : 307 -314.
  • 6Clauson P, Karland S, Steen L, et al. Daytime glibenclamide and bedtime insulin compared to intensive insulin treatment in secondary sulphonylurea failure:a 1-year follow-up. Diabet Med, 1996,13(5) :471 ~ 477.
  • 7UKPDS Group. A 6-year randomized prospective controlled trial comparing sulfonylurea, insulin and mefformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med,1998,128(3) :165-175
  • 8Buse JB, Gumbiner B, Mathias NP, et al. Troglitazone use in insulintreated type 2 diabetes patients. Disbet Care, 1998,21(9): 1455-1461
  • 9Paskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabet Care,2001,24(7):1226-1232
  • 10Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diabet Med,2002,19(7):572-574

共引文献5

同被引文献15

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部